Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
35
DERM Quote, Financials, Valuation and Earnings
Last price:
$7.82
Seasonality move
:
-10.92%
Day range:
$7.54 - $8.01
52-week range:
$3.54 - $9.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.06x
P/B ratio:
8.18x
Volume:
76.8K
Avg. volume:
220.8K
1-year change:
39.71%
Market cap:
$211.9M
Revenue:
$56.1M
EPS (TTM):
-$0.37
Analysts' Opinion
-
Consensus RatingJourney Medical Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.50, Journey Medical Corp. has an estimated upside of 72.86% from its current price of $7.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $7.81.
Fair Value
-
According to the consensus of 4 analysts, Journey Medical Corp. has 72.86% upside to fair value with a price target of $13.50 per share.
DERM vs. S&P 500
-
Over the past 5 trading days, Journey Medical Corp. has underperformed the S&P 500 by -0.37% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Journey Medical Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Journey Medical Corp. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Journey Medical Corp. reported revenues of $17.6M.
Earnings Growth
-
Journey Medical Corp. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Journey Medical Corp. reported earnings per share of -$0.09.
Enterprise value:
212.3M
EV / Invested capital:
4.15x
Price / LTM sales:
3.06x
EV / EBIT:
40.15x
EV / Revenue:
3.57x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-11.21x
Price / Operating cash flow:
58.24x
Enterprise value / EBITDA:
17.03x
Gross Profit (TTM):
$35.1M
Return On Assets:
-10.95%
Net Income Margin (TTM):
-14.58%
Return On Equity:
-44.34%
Return On Invested Capital:
-19.67%
Operating Margin:
-8.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $79.9M | $57.8M | $59.4M | $14.6M | $17.6M | |
| Gross Profit | $51.5M | $33.1M | $35.1M | $9.3M | $10.8M | |
| Operating Income | -$6.3M | -$18M | -$10M | -$2.9M | -$1.5M | |
| EBITDA | -$2.1M | -$14.7M | -$5.8M | -$2.1M | -$443K | |
| Diluted EPS | -$0.84 | -$0.92 | -$0.37 | -$0.12 | -$0.09 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $66.8M | $79.6M | $44.7M | $46.2M | $56.4M | |
| Total Assets | $89.1M | $108.1M | $65.9M | $64M | $85.2M | |
| Current Liabilities | $59.8M | $60.8M | $48.5M | $33.3M | $39.7M | |
| Total Liabilities | $100.8M | $82M | $48.5M | $53.1M | $59.3M | |
| Total Equity | -$11.7M | $26.2M | $17.4M | $10.9M | $25.9M | |
| Total Debt | $41.1M | $21.2M | $34K | $19.8M | $19.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $17.8M | -$27.8M | -$3.9M | -$1.2M | -$2.4M | |
| Cash From Investing | -$5M | -- | -$15M | -- | -- | |
| Cash From Financing | -$23M | $25.5M | $21.4M | -$294K | $7M | |
| Free Cash Flow | $12.8M | -$27.8M | -$18.9M | -$1.2M | -$2.4M | |
DERM
Sector
Market Cap
$211.9M
$28.4M
Price % of 52-Week High
83.09%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-9.72%
-1.32%
1-Year Price Total Return
39.71%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.74
200-day SMA
Buy
Level
$7.04
Bollinger Bands (100)
Buy
Level
7 - 8.06
Chaikin Money Flow
Buy
Level
3.2M
20-day SMA
Sell
Level
$8.06
Relative Strength Index (RSI14)
Sell
Level
48.96
ADX Line
Sell
Level
19.95
Williams %R
Neutral
Level
-40.6593
50-day SMA
Buy
Level
$7.77
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
8.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.5104)
Sell
CA Score
(Annual)
Level (-2.3453)
Buy
Beneish M-Score
(Annual)
Level (-2.8707)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (3.4185)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Stock Forecast FAQ
In the current month, DERM has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DERM average analyst price target in the past 3 months is $13.50.
-
Where Will Journey Medical Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Journey Medical Corp. share price will rise to $13.50 per share over the next 12 months.
-
What Do Analysts Say About Journey Medical Corp.?
Analysts are divided on their view about Journey Medical Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Journey Medical Corp. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Journey Medical Corp.'s Price Target?
The price target for Journey Medical Corp. over the next 1-year time period is forecast to be $13.50 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DERM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Journey Medical Corp. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DERM?
You can purchase shares of Journey Medical Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Journey Medical Corp. shares.
-
What Is The Journey Medical Corp. Share Price Today?
Journey Medical Corp. was last trading at $7.82 per share. This represents the most recent stock quote for Journey Medical Corp.. Yesterday, Journey Medical Corp. closed at $7.81 per share.
-
How To Buy Journey Medical Corp. Stock Online?
In order to purchase Journey Medical Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DERM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DERM
Sector
P/E ratio
--
23.66x
PEG ratio
0.00x
-0.01x
P/B ratio
8.18x
1.84x
Price / LTM sales
3.06x
1.60x
Growth Metrics
DERM
Sector
Revenue growth
20.52%
4.85%
Earnings growth
20.28%
11.15%
Revenue (5-year growth)
9.96%
6.45%
Earnings forecast
--
-$0.20
Profitability
DERM
Sector
Profitability FY 2024
$31.8M
$3.6M
Return on invested capital
-19.67%
-30.98%
Return on assets
-10.95%
-27.62%
Return on equity
-44.34%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
11
Balance Sheet
DERM
Sector
Total cash
$24.9M
$27.2M
Short term investments
--
$25.7M
Total assets
$80.2M
$79.9M
Long term debt
$19.6M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
